acute coronary syndrome

Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
Yahoo/Benzinga
Amarin
Vascepa
Vazkepa
acute coronary syndrome
clinical trials
Flag link:
AstraZeneca heart drug gets preferred status in U.S.
AstraZeneca heart drug gets preferred status in U.S.
Yahoo/Reuters
AstraZeneca
Brilinta
acute coronary syndrome
Flag link:
GSK starts phase III of coronary drug test
GSK starts phase III of coronary drug test
Reuters
GSK
losmapimod
acute coronary syndrome
Flag link:
FDA advisory panel rejects J&J drug for acute coronary syndrome
FDA advisory panel rejects J&J drug for acute coronary syndrome
Reuters
JNJ
acute coronary syndrome
Xarelto
advisory panels
FDA
Flag link:
Losing the Battle and the War
Losing the Battle and the War
Motley Fool
JNJ
Xarelto
acute coronary syndrome
Flag link:
Losing the Battle and the War
Losing the Battle and the War
Motley Fool
JNJ
Xarelto
acute coronary syndrome
Flag link:
Biotechs Have No Business in This Indication
Biotechs Have No Business in This Indication
Motley Fool
Anthera
acute coronary syndrome
Flag link:
Anthera halts late-stage heart drug trial, shares tank
Anthera halts late-stage heart drug trial, shares tank
Reuters
Anthera
VISTA-16
acute coronary syndrome
Flag link:
Bayer, J&J clot drug to get fast FDA review for ACS
Bayer, J&J clot drug to get fast FDA review for ACS
Reuters
Bayer
FDA
JNJ
Xarelto
fast track
acute coronary syndrome
Flag link:
Merck's Vorapaxar Disappoints
Merck's Vorapaxar Disappoints
Yahoo/Zacks
Merck
Vorapaxar
acute coronary syndrome
anticlotting
Flag link:
ATLAS ACS 2-TIMI 51: Rivaroxaban Beneficial in Low-Risk ACS Population
ATLAS ACS 2-TIMI 51: Rivaroxaban Beneficial in Low-Risk ACS Population
Forbes
rivaroxaban
Xarelto
acute coronary syndrome
anticoagulants
anti-platelets
Flag link:
TRACER: Novel Antiplatelet Vorapaxar Runs Into Trouble in ACS
TRACER: Novel Antiplatelet Vorapaxar Runs Into Trouble in ACS
Forbes
Vorapaxar
TRACER
acute coronary syndrome
anti-platelet
Merck
Flag link:
Rivaroxaban Meets Primary Endpoint in ATLAS ACS TIMI 51
Rivaroxaban Meets Primary Endpoint in ATLAS ACS TIMI 51
Forbes
rivaroxaban
JNJ
Xarelto
acute coronary syndrome
Bayer
Flag link:
Should You Buy It?: Anthera Pharmaceuticals
Should You Buy It?: Anthera Pharmaceuticals
Motley Fool
Anthera
acute coronary syndrome
lupus
Flag link:
FDA Pushes Out Brilinta Action Date
FDA Pushes Out Brilinta Action Date
Yahoo/Zacks
AstraZeneca
Brilinta
acute coronary syndrome
Plavix
Bristol-Myers Squibb
Flag link:
Anthera's Lead Drug: A High-Risk, High-Reward Proposition
Anthera's Lead Drug: A High-Risk, High-Reward Proposition
Seeking Alpha
Anthera
A-002
acute coronary syndrome
GSK
darapladib
Flag link: